JD Health Intl (OTC:JDHIF) Stock, Quote.Headers.trade-ideas

JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health, Ping An Good Doctor, and Meituan for its e-commerce business. As of Dec. 31, 2023, the platform has over 180 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com

Asia

Markets

General

ALBBY

JDHIF

Key Takeaways:


	The gross margin on the company’s proprietary drug distribution business, its main revenue source, edged down to 6.1% last year
	With the pharma market already well developed, several distribution giants have muscled onto YSB’s turf as suppliers to pharmacies and smaller clinics


By Molly Wen

Slowing Revenue Growth Hurts Online Drug Platform YSB

Fintech news covering the emerging Financial Technology services sector

Fintech

Penny Stocks

ALBHF

PANHF

Key takeaways:


	111’s revenue grew 87% in second quarter, generally outpacing its peers, as it aims to more than double its fulfillment capacity this year
	Company’s shares now trade around $6.50, well off a $23 high reached in February, as investors worry about regulatory wave for broader tech sector


By Mia Shanley

Solid Earnings, Modest Buyback Fail to Boost Drug Seller 111 Inc.

JD HEALTH INTL INC by JD HEALTH INTL INC.

JD Health International Inc

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="8" rowspan="1">Passenger Traffic, Cargo Volume and Aircraft Movements Highlights (2024 vs. 2023)</td>
<td colspan="4" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Statistics</td>
<td colspan="1" rowspan="1">Dec'24</td>
<td colspan="1" rowspan="1">Dec'23</td>
<td colspan="1" rowspan="1">% Var.</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">FY'24</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">FY'23</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">% Var.</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Domestic Passengers (thousands)</td>
<td colspan="1" rowspan="1">3,772</td>
<td colspan="1" rowspan="1">3,854</td>
<td colspan="1" rowspan="1">-2.1%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">40,996</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">45,679</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-10.3%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">International Passengers (thousands)</td>
<td colspan="1" rowspan="1">2,554</td>
<td colspan="1" rowspan="1">2,293</td>
<td colspan="1" rowspan="1">11.4%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">30,758</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">28,362</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">8.4%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Transit Passengers (thousands)</td>
<td colspan="1" rowspan="1">639</td>
<td colspan="1" rowspan="1">600</td>
<td colspan="1" rowspan="1">6.4%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">7,227</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">7,106</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1.7%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Passengers (thousands)1</td>
<td colspan="1" rowspan="1">6,965</td>
<td colspan="1" rowspan="1">6,747</td>
<td colspan="1" rowspan="1">3.2%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">78,981</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">81,147</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-2.7%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cargo Volume (thousand tons)</td>
<td colspan="1" rowspan="1">39.5</td>
<td colspan="1" rowspan="1">36.1</td>
<td colspan="1" rowspan="1">9.3%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">398.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">370.2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">7.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Aircraft Movements (thousands)</td>
<td colspan="1" rowspan="1">73.3</td>
<td colspan="1" rowspan="1">71.5</td>
<td colspan="1" rowspan="1">2.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">823.7</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">849.5</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">-3.0%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">1 Excluding Natal for comparison purposes, total passenger traffic was up 6.6% in December and down 0.4% for FY 2024.</td>
</tr>
</tbody>
</table>
</figure>
Passenger Traffic Overview
Total passenger traffic increased by 3.2% in December compared to the same month in 2023, or by 6.6% when adjusted for the discontinuation of operations at Natal Airport. Domestic passenger traffic decreased by 2.1% year-over-year but increased by 3.3% when excluding Natal. This growth was primarily driven by strong performance in Italy and a recovery in domestic traffic in Argentina. International traffic increased by 11.4%, mainly driven by growth in Argentina and Italy.

News

CAAP

Reported Monday, Corporación América Airports S.A. Reported December 2024 Passenger Traffic: Total Passenger Traffic Down 3.2% YoY, Or Up 6.6% YoY Ex-Natal; International Passenger Traffic Up 11.4% YoY

Headquartered in North Hollywood, California, Cryo-Mach is a specialized designer and manufacturer of mission-critical cryogenic centrifugal pumps, mechanical seals, and accessories. Cryo-Mach's products will expand Dover's participation in cryogenic applications, such as liquified oxygen, argon, and nitrogen, and allows further participation in the industrial gas and transportation markets. The acquisition also expands PSG's core portfolio with cryogenic centrifugal pump technology while further diversifying PSG within the cryogenic end market.

Reported Monday, Dover Expands Cryogenic Capabilities With Acquisition Of Cryogenic Machinery Corp.

The one-year VLA1553-321 data showed that a single-dose vaccination induced a high, sustained immune response in an immunogenicity subset of participants who were CHIKV negative at baseline, with a seroresponse rate of 98.3% (232 out of 236 participants) one year after vaccination (Day 360) compared to 99.1% (232 out of 234 participants) after six month3 (Day 180) and 98.8% (248 out of 251 participants) 28 days4,5 after vaccination. The results complement the long-term persistence data previously reported for adults6, confirming a strong and long-lasting antibody response to the vaccine.

VALN

Reported Monday, Valneva Reports 98.3% Seroresponse One Year After Single Chikungunya Vaccine In Adolescents

CLRO

Reported Monday, ClearOne Launches Versa 120D For Hybrid Meeting Excellence With Dante And USB-C Integration

AAOI

Reported Monday, CIG USA Seeks Patent Review In Legal Battle With Applied Optoelectronic

VZLA

Reported Monday, Vizsla Silver Resumes Limited Operations At Panuco Silver-Gold Project

Reported Monday, Pyramid Consulting Teams Up With Dynatrace To Deliver Unified Observability And Automation Solutions

Reported Monday, Quantum-Si To Present Next-Generation Protein Sequencing At Festival Of Genomics UK

Positive Reimbursement&nbsp;Recommendations&nbsp;by Canada's Drug Agency and Institut National d'excellence en Santé et Services Sociaux
Positive Reimbursement&nbsp;Recommendations&nbsp;by Canada's Drug Agency and Institut National d'excellence en Santé et Services Sociaux

Reported Monday, Takeda's FRUZAQLA (fruquintinib) Receives Health Canada Approval For Metastatic Colorectal Cancer

<h3>Companies Reporting Before The Bell</h3>
• 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) is estimated to report quarterly earnings at $1.66 per share on revenue of $5.78 billion. 
• United Microelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $1.87 billion. 
• Complete Solaria (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) is expected to report quarterly loss at $0.21 per share on revenue of $76.50 million. 
• Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) is estimated to report quarterly earnings at $0.46 per share on revenue of $485.57 million. 
• Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $2.21 billion. 
• FB Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) is estimated to report quarterly earnings at $0.83 per share on revenue of $131.14 million. 
• KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $1.75 billion. 
• Mercantile Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBWM#NASDAQ">MBWM</a>) is projected to report quarterly earnings at $1.14 per share on revenue of $57.33 million. 
• Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) is projected to report quarterly earnings at $1.38 per share on revenue of $1.94 billion. 
• Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) is expected to report quarterly earnings at $0.61 per share on revenue of $29.49 million. 
• Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) is likely to report quarterly earnings at $0.89 per share on revenue of $5.13 billion. 
• Peoples Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBO#NASDAQ">PEBO</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $109.93 million. 
• Forestar Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>) is estimated to report quarterly earnings at $0.70 per share on revenue of $328.44 million. 
• New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $1.06 billion. 
• Community Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBU#NYSE">CBU</a>) is projected to report quarterly earnings at $0.89 per share on revenue of $192.78 million. 
• D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) is estimated to report quarterly earnings at $2.39 per share on revenue of $7.12 billion. 
<h3>Companies Reporting After The Bell</h3>
• Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) is estimated to report quarterly earnings at $1.26 per share on revenue of $787.50 million. 
• United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) is expected to report quarterly earnings at $3.01 per share on revenue of $14.34 billion. 
• SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $44.37 million. 
• Simmons First Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFNC#NASDAQ">SFNC</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $208.67 million. 
• Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is likely to report quarterly earnings at $4.20 per share on revenue of $10.13 billion. 
• Trustco Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRST#NASDAQ">TRST</a>) is likely to report earnings for its fourth quarter. 
• Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) is likely to report quarterly earnings at $1.22 per share on revenue of $211.34 million. 
• Interactive Brokers Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) is projected to report quarterly earnings at $1.82 per share on revenue of $1.37 billion. 
• Hancock Whitney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWC#NASDAQ">HWC</a>) is likely to report quarterly earnings at $1.28 per share on revenue of $365.13 million. 
• Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) is expected to report quarterly earnings at $1.78 per share on revenue of $470.83 million. 
• Agilysys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) is estimated to report quarterly earnings at $0.34 per share on revenue of $73.15 million. 
• Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) is expected to report quarterly earnings at $1.87 per share on revenue of $2.32 billion. 
• Pathward Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASH#NASDAQ">CASH</a>) is expected to report quarterly earnings at $1.24 per share on revenue of $171.35 million. 
• Fulton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $315.73 million. 
• Great Southern Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSBC#NASDAQ">GSBC</a>) is expected to report quarterly earnings at $1.32 per share on revenue of $55.33 million. 
• Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) is projected to report quarterly earnings at $2.49 per share on revenue of $632.53 million. 
• Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) is projected to report quarterly earnings at $2.71 per share on revenue of $10.21 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

AGYS

CASH

CSLR

New Oriental Education & Technology Group

FITB

FULT

GNTY

GSBC

IBKR

MBWM

NFLX

PEBO

PNFP

PRGS

SCHW

SFNC

SMBK

TRST

WTFC

ZION

Earnings Scheduled For January 21, 2025

UHAL

Reported Monday, U-Haul Adds Climate-Controlled Storage Units In Marietta With New Two-Story Facility

Customers in the U.S. looking to purchase an electric vehicle can get a $7500 federal EV tax credit for several models including from Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), and more. However, President Donald Trump on Monday said that his administration would consider ending tax credits, impacting the purchase price for eligible customers.
Vehicles That Qualify: The various Tesla electric vehicles eligible for $7,500 include select trims of the Cybertruck, Model 3, Model X, and Model Y. Other brand vehicles that qualify include the Kia EV9 and selected trims of the F-150 Lightning truck.
The only Plug-in Hybrid that qualifies for the credit is the Chrysler Pacifica PHEV.
The list of vehicles that qualify for the tax credit right now is as follows:
<ul>
<li>Acura ZDX</li>
<li>Cadillac Lyriq (Luxury and Sport Models)</li>
<li>Cadillac Optiq</li>
<li>Chevrolet Blazer EV (LT, RS, and SS Models)</li>
<li>Chevrolet Equinox EV (LT and RS Models)</li>
<li>Chevrolet Silverado EV (LT Model)</li>
<li>Ford F-150 Lightning (Flash, Lariat and XLT Trims)</li>
<li>Honda Prologue</li>
<li>Jeep Wagoneer S</li>
<li>Kia EV6</li>
<li>Kia EV9</li>
<li>Tesla Cybertruck (Single Motor and Dual Motor)</li>
<li>Tesla Model 3 (Long Range AWD, Long Range RWD, Performance variants)</li>
<li>Tesla Model X (AWD Variant)</li>
<li>Tesla Model Y (Long Range AWD, Long Range RWD, Performance variants)</li>
<li>Chrysler Pacifica PHEV</li>
</ul>
Trump&#8217;s Take On EV Tax Credits: In November, Reuters reported that Donald Trump‘s transition team plans to kill the $7,500 tax credit available on EV purchases. On Monday, after his inauguration, Trump himself said his administration would consider ending EV tax credits.
&#8220;The Republicans have a very small majority in the House, which could make it hard for the party to pass legislation of any kind,&#8221; The Future Fund Managing Partner Gary Black said about a possible repeal of the tax credit on Monday. &#8220;Another wild card is Elon Musk, with $TSLA accounting for nearly half of all EVs sold in the country. With Elon Musk close to the president, it is important to know how he will seek to shape changes to the tax credit. Other auto executives have also been lobbying Mr. Trump against a repeal of the credit. Among them is Ford's executive chairman, William C. Ford Jr., who recently spoke to the president-elect.&#8221;
However, Tesla CEO Elon Musk, a close Trump ally, has previously supported scrapping of the tax credit. 
"In my view, we should end all government subsidies, including those for EVs, oil and gas," Musk said in November.
During Tesla&#8217;s second-quarter earnings in late July, Musk also said that the impact of the elimination of subsidies&nbsp;<a href="https://www.benzinga.com/news/24/07/39934750/trump-presidency-and-ira-cut-would-be-devastating-for-competitors-says-elon-musk-long-term-probably" target="_blank" rel="noreferrer noopener">would only be slight for Tesla</a>&nbsp;but devastating for its competitors. The elimination of EV subsidies would probably help Tesla in the long term, he added.
However, not all are in agreement. Tesla researcher Troy Teslike has previously said that the loss of tax credit will only make Tesla<a href="https://www.benzinga.com/24/12/42641207/researcher-says-cancelation-of-7500-ev-tax-credit-could-impact-teslas-deliveries-despite-ceo-elon-musk-claiming-otherwise" target="_blank" rel="noreferrer noopener">&nbsp;lose its market to gas cars</a>&nbsp;from luxury car brands.
Trump, on Monday also revoked a 2021 executive order signed by former President Joe Biden that sought to ensure that 50% of new vehicles sold in the U.S. by 2020 are electric.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43080738/nhtsa-opens-probe-into-about-878000-gm-gas-vehicles-days-after-closing-investigation-into-its-cruise-avs" target="_blank" rel="noreferrer noopener">NHTSA Opens Probe Into Nearly 878,000 GM Vehicles Over Engine Failure Concerns Days After Closing Investigation Into Its Cruise AVs</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration

Amcon Distributing (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DIT#AMEX">DIT</a>) reported quarterly earnings of $0.57 per share. This is a 67.98 percent decrease over earnings of $1.78 per share from the same period last year. The company reported $711.27 million in sales this quarter. This is a 10.28 percent increase over sales of $644.96 million the same period last year.

Reported Monday, Amcon Distributing Q1 EPS $0.57 Down From $1.78 YoY, Sales $711.27M Up From $644.96M YoY

<ul>
<li>Significant portfolio expansion to include combat-proven autonomous airborne platforms in support of critical forward-looking national security mission needs</li>
<li>Expected to be immediately accretive to Revenue, Adjusted EBITDA and Free Cash Flow</li>
<li>Post-transaction, Redwire expects to have a strong balance sheet</li>
</ul>

Reported Sunday, Redwire To Acquire Edge Autonomy In $925M Deal, Transforming Into A Multi-Domain Space And Defense Leader

Collaboration will bring bespoke content and never-before-seen show integrations

Reported Sunday, BetMGM Secures Online Casino Rights For Fremantle's "Family Feud" And "The Price Is Right"

Programming Already Restored for Two Million Viewers, Including NFL Playoff Games and Local News

ATUS

NXST

Reported Saturday, Nexstar And Optimum Reach Agreement To Restore Programming For Two Million Customers

<a href="https://www.globenewswire.com/Tracker?data=ZJKetO8zE3erzqRGF_P7-sCgwYhySBueJMgNqynfM3aNltyVHIqgYbS_u8Uz3Nv7SKdETdCLI16Ppo7Wvc4v8A==">NANOBIOTIX</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (<a href="https://www.globenewswire.com/Tracker?data=9AF1jPR-HWZ8jVuLKKF7MX10tUChZ_X2NGuXvAVUyFwhfw23CgjxX9aY63wN0Kdaec4QfEQsIuazNYZjxTvGX2JHp8IO-l0T8OXn7FrEKgkLxinTtGOoP8RlFCRY0HK-ieJqCKDibtD2Daq_RvrOBA==">NCT06667908</a>). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson &amp; Johnson Company, under a global license agreement.

NBTX

Nanobiotix Begins Phase 2 Trial for Innovative Cancer Treatment in Stage 3 Lung Cancer

ARBK

Argo Blockchain CEO Thomas Chippas To Exit; CFO Jim MacCallum Appointed As Interim Successor

The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/SCHW/earnings">opening bell, on Tuesday, Jan. 21, 2025.</a>
Analysts expect the Westlake, Texas-based company to report quarterly earnings at 91 cents per share, up from 68 cents per share in the year-ago period. Charles Schwab projects quarterly revenue of $5.2 billion, compared to $4.46 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 13, Charles Schwab said it expects FY24 net revenue to grow by 3.0%-3.5% versus the prior year.
Charles Schwab shares gained 1.2% to close at $76.41 on Friday&nbsp;&nbsp;&nbsp; .
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SCHW/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Wells Fargo analyst Michael Brown maintained an Equal-Weight rating and cut the price target from $90 to $89 on Jan. 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Christopher Allen maintained a Neutral rating and cut the price target from $85 to $80 on Jan. 10, 2025. This analyst has an accuracy rate of 77%.</li>
<li>JP Morgan analyst Kenneth Worthington maintained an Overweight rating and raised the price target from $87 to $93 on Jan. 7, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Piper Sandler analyst Patrick Moley maintained a Neutral rating and raised the price target from $65 to $70 on Jan. 7, 2025. This analyst has an accuracy rate of 81%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintained an Outperform rating and raised the price target from $81 to $93 on Dec. 20, 2024. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-1024x576.png" alt="" class="wp-image-741030" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43054647/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Comments

JD Health Intl

JD Health Intl (JDHIF) Forecast

JD Health Intl (OTC:JDHIF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga